| Species |
Human |
| Protein Construction |
IL-7 (Asp26-His177)
Accession # P13232 |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 0.01EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized IL-7, Human at 2μg/ml (100μl/Well) on the plate can bind Human IL7R alpha, hFc Tag. Test result was comparable to standard batch.
Measured in a cell proliferation assay using murine 2E8 cells. The ED50 for this effect is 0.1 0.5 ng/mL. Test result was comparable to standard batch. |
| Expression System |
E.coli |
| Theoretical Molecular Weight |
17.5 kDa |
| Apparent Molecular Weight |
The protein has a predicted MW of 17.5 kDa same as Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 8.0). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Interleukin-7 (IL7) plays a nonredundant role in T cell survival and homeostasis, which is illustrated in the severe T cell lymphopenia of IL7-deficient mice, or demonstrated in animals or humans that lack expression of either the IL7Rα or γ c chain, the two subunits that constitute the functional IL7 receptor. |
| Synonyms |
IL7; Interleukin-7; IL-7; Lymphopoietin-1; PBGF |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
